Vision Disorders and Phosphodiesterase Type 5 Inhibitors

@article{Laties2009VisionDA,
  title={Vision Disorders and Phosphodiesterase Type 5 Inhibitors},
  author={A. Laties},
  journal={Drug Safety},
  year={2009},
  volume={32},
  pages={1-18}
}
Phosphodiesterase type 5 (PDE-5) inhibitors (sildenafil, vardenafil and tadalafil) have been in widespread use for the safe and effective treatment of erectile dysfunction (ED) for nearly a decade. During that time, a relatively small number of patients have experienced adverse visual events, including nonarteritic anterior ischaemic optic neuropathy (NAION). In this article, post-marketing reports of adverse visual events along with other relevant literature on ocular safety related to PDE-5… Expand
Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction
Tadalafil for the treatment of pulmonary arterial hypertension
  • J. Klinger
  • Medicine
  • Expert review of respiratory medicine
  • 2011
Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment
Ocular toxicity assessment of chronic sildenafil therapy for pulmonary arterial hypertension
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 125 REFERENCES
Optic atrophy after sildenafil use.
Non-arteritic anterior ischemic optic neuropathy (NAION) and phosphodiesterase type-5 inhibitors.
Ocular safety in patients using sildenafil citrate therapy for erectile dysfunction.
Viagra® (sildenafil citrate) and ophthalmology
PDE5 inhibitors and permanent visual loss
  • R. Tomsak
  • Medicine
  • International Journal of Impotence Research
  • 2005
Ischemic optic neuropathy in male veterans prescribed phosphodiesterase-5 inhibitors.
Sildenafil in erectile dysfunction: a critical review
Sildenafil-associated nonarteritic anterior ischemic optic neuropathy.
Tadalafil-associated anterior ischaemic optic neuropathy
...
1
2
3
4
5
...